tbuckley/cabot-search huggingface dataset:
Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC)
Authors: A. Muñoz, A. Salud, V. Alonso, P. Escudero, J. J. Sanz, C. Martín, F. Rivera, A. Yubero, C. García-Girón, G. López-Vivanco
Journal: Journal of Clinical Oncology (2004)

3610 Background: CPT-11 plus 5-FU is standard first-line therapy in patients with MCRC. X is an oral prodrug of FU, which provides continuous fluoropyrimidine exposure without the inconvenience of an infusional therapy. We design a phase II study to evaluate the RR of both drugs. Secondary objectives were safety profile, TTP and OS. Methods: Patients with histologically confirmed LA or MCRC, measurable disease, ECOG PS ≤2 and adequate bone marrow, renal and hepatic functions were included. Previous adjuvant chemotherapy was allowed if finished ≥6 months before starting study treatment. Patients received 225 mg/m2 of CPT-11 (180 mg/m2 if > 65 years old) on D1 as a 90-min iv infusion and 2000 mg/m2/day po of X (1500 mg/m2 if >65 years old) from D2–15. Cycles were every 21 days until progressive disease, excessive toxicity or consent withdrawal. Results: Ninety-one patients were enrolled (M/F, 56/35). Median age was 67 (30–80), 55% > 65 years. ECOG PS 0–1: 92%. Primary tumor sites were colon (59%), rectum (36%) or both (5%). Median No. of metastatic lesions was 4 (93% with ≥2 sites) in liver (71%), lung (42%), lymph nodes (21%) and local recurrence (15%). 24% of patients received previous adjuvant chemotherapy. Up to date, 562 cycles (median 6, range 1–17) were administered. Median RDI was 97% for X and 94% for CPT-11 (100% and 99% for patients > 65 years old). All patients were evaluable for toxicity. In patients >65/≤65 years old, main grade 3/4 toxicity per cycle were neutropenia 9%/4%, leukopenia 5%/3%, asthenia 4%/3% and diarrhoea 6%/3%. Febrile neutropenia was observed in 2 patients, 1 cycle each. There were 3 treatment related deaths (2 > 65 years old). Efficacy: In 79 evaluable patients, 3 achieved CR, 30 PR, 33 SD and 13 progressed, resulting in an ORR of 42% (95% CI: 31–53) and tumour growth control (RR + SD) in 84% of patients. With a median follow-up of 6.7 months, TTP was 10,3 months (95% CI: 8.7–11.9) and OS was 15.9 months (95% CI: 14.0–17.8). Conclusions: CPT-11 and X as first-line treatment of LA or MCRC is an active schedule with a manageable toxicity profile, even in patients older than 65 years. No significant financial relationships to disclose.
Abstract 16381: Novel Thiol-activated H2S Donors Attenuate Myocardial Ischemia/Reperfusion Injury
Authors: Chelsea Organ, Zhen Li, Yu Zhao, Chuntao Yang, Shashi Bhushan, Hiro Otsuka, Ming Xian, David J Lefer
Journal: Circulation (2015)

Background: Hydrogen sulfide (H2S) protects against acute myocardial ischemia/reperfusion (MI/R) injury and heart failure by ameliorating oxidative stress, improving mitochondrial function, and attenuating apoptosis. One of the major limitations of currently available H2S donors is poor pharmacokinetics profiles that result in very rapid and uncontrolled H2S release. NSHD-1 and NSHD-2 are recently developed thiol-activated H2S donors designed for sustained release of H2S upon activation by molecules containing thiol groups such as cysteine and glutathione. We hypothesized that these novel H2S donors would generate H2S for extended periods and ameliorate myocardial cell death following MI/R in an in vivo murine model. Methods and Results: C57BL6/J male mice (10-12 weeks of age) were subjected to 45 minutes of MI followed by 24 hours of R. At the time of reperfusion, animals received Vehicle (0.5% THF), NSHD-1 (50 μg/kg and 100 μg/kg), or NSHD-2 (50 μg/kg) by direct intracardiac (i.c.) injection. In addition, at 4 hours of R, plasma was collected for troponin-I measurements. In preliminary studies we observed sustained release of H2S with both of these H2S donors. Myocardial infarct size was reduced by 35% (p &lt; 0.01 vs. Vehicle) in mice treated with NSHD-1 (100 μg/kg), 43% (p &lt; 0.05 vs. Vehicle) in mice treated with NSHD-2 (50 μg/kg), and 54% (p &lt; 0.01 vs. Vehicle) in mice treated with NSHD-2 (100 μg/kg). Conclusions: NSHD-1 and NSHD-2 significantly attenuate MI/R injury in a murine model. Experiments are currently underway to further define the in vivo pharmacokinetics of H2S release from these agents, mechanisms of action, and safety profile.
Tick-borne typhus (Rocky Mountain spotted fever). Epidemiologic trends, with particular reference to Virginia
Authors: A. H. Peters
Journal: JAMA (1971)

In 1969, there was more than a 50% increase in the reported incidence of tick-borne typhus in the United States. This dramatic increase caps a ten-year trend of an ever-increasing number of cases of this disease. Virginia led the states in the major endemic area of the nation, the Piedmont plateau of the Southeast, with 91 reported cases. Yearly fluctuations may be attributable to climatic conditions influencing the relative number of ticks, but the long-term trend of increasing human morbidity is promoted by the apparently inexorable forces of population growth and land-use changes. More attention to precautionary measures by the public, as well as a heightened awareness of physicians, in major endemic states may prevent some deaths. Treatment should not await serological confirmation.
Modulation of Mitochondrial Gene Expression in Pulmonary Epithelial Cells Exposed to Oxidants
Authors: Yvonne M. W. Janssen, Kevin E. Driscoll, Cynthia R. Timblin, Diane Hassenbein, Brooke T. Mossman
Journal: Environmental Health Perspectives (1998)

Oxidants are important in the regulation of signal transduction and gene expression.Multiple classes of genes are transcriptionally activated by oxidants and are implicated in different phenotypic responses.In the present study, we performed differential mRNA display to elucidate genes that are induced or repressed after exposure of rat lung epithelial (RLE) cells to H202 or crocidolite asbestos, a pathogenic mineral that generates oxidants.After 8 or 24 hr of exposure, RNA was extracted, reverse transcribed, and amplified by polymerase chain reaction with degenerate primers to visualize alterations in gene expression.The seven clones obtained were sequenced and encoded the mitochondrial genes, NADH dehydrogenase subunits ND5 and ND6, and 16S ribosomal RNA.Evaluation of their expression by Northern blot analysis revealed increased expression of 16S rRNA after 1 or 2 hr of exposure to H202.At later time periods (4 and 24 hr), mRNA levels of 16S rRNA and NADH dehydrogenase were decreased in H202- treated RLE cells when compared to sham controls.Crocidolite asbestos caused increases in 1 6S rRNA levels after 8 hr of exposure, whereas after 24 hr of exposure to asbestos, 16S rRNA levels were decreased in comparison to sham controls.In addition to these oxidants, the nitric oxide generator spermine NONOate caused similar decreases in NADH dehydrogenase mRNA levels after 4 hr of exposure.The present data and previous studies demonstrated that all oxidants examined resulted in apoptosis in RLE cells during the time frame where alterations of mitochondrial gene expression were observed.As the mitochondrion is a major organelle that controls apoptosis, alterations in expression of mitochondrial genes may be involved in the regulation of apoptosis.
Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary safety results of a phase III study
Authors: J. Fahlke, K. Ridwelski, C. Schmidt, E. Kettner, D. Quitzsch, U. Keilholz, M. Assmann, A. Florschuetz, M. Stauch, H. Lippert
Journal: Journal of Clinical Oncology (2005)

4045 Background: No consensus currently exists on the best treatment regimen for advanced gastric cancer. Based on promising Phase II studies, this randomized, multicenter Phase III study compared DC with a commonly used regimen, FLC. Methods: Patients aged 18–75 years with stage III (T4, nonresectable) or IV gastric cancer, Karnofsky performance status (KPS) ≥60%, and life expectancy ≥3 months were randomized to receive ≤6 cycles of DC (D 75 mg/m2 and C 75 mg/m2; both as 1-h infusions d1q3w) or ≤4 cycles of FLC (F 2000 mg/m2 [24-h infusion] and L 500 mg/m2 [2-h infusion], both d1, 8, 15, 22, 29, 36 q7w, plus C 50 mg/m2 [1-h infusion], d1, 15, 29 q7w). C was omitted in FLC Cycle 4. Treatment was stopped in the event of disease progression, intolerable toxicity, or consent withdrawal. Tumors were staged on D 40, 85, 135, and 190. The study endpoints were time to progression (primary) and toxicity, response rate, quality of life, and overall survival (secondary). Planned accrual was 216 patients; 196 evaluable patients were needed to detect a clinically meaningful increase (from 40% to 60%) in patients without progression at 6 months (2-tailed type I error 0.05; 80% power). Results: At 9 months’ follow-up preliminary safety data are available for 162 patients (81 per arm; median age 63 [range: 32–79] years; median KPS 80% [range: 60–100%]; adenocarcinoma ≈80%; Lauren type 48%, diffuse type 43%). Baseline characteristics were similar in both arms. Median cycles administered were 5 (DC) and 2 (FLC). Grade 3–4 hematologic toxicities were more frequent with DC vs FLC (leukopenia 40% vs 5%; neutropenia 35% vs 5%; anemia 11% vs 7%), but there were few cases of grade 3–4 febrile neutropenia (4% vs 0%), fever (1% vs 0%) or infections (5% vs 5%). Major grade 3–4 nonhematologic toxicities with DC vs FLC were nausea (14% vs 17%) and vomiting (7% vs 12%). Conclusions: DC was well tolerated with a predictable toxicity profile. Greater hematologic toxicity was seen with DC than FLC, but complications were rare. The study is ongoing and efficacy results are awaited. No significant financial relationships to disclose.
Health center impact on hospital utilization
Authors: G. T. Moore
Journal: JAMA (1974)

Hospital utilization was studied one year before and again two years after the opening of a neighborhood health center, to determine the effect of the health center on hospital use by residents of the community. Per capita admissions to the hospital affiliated with the health center increased by 56.1%. Study of a matched subsample of the community demonstrated a shift of use, as measured by hospital expenditures, to the affiliated hospital, with a slight decrease in the use of other hospitals. Hospital expenditures by this subsample increased substantially between the two years, suggesting an overall increase in hospital use by the community's residents. (<i>JAMA</i>228:332-333, 1974)
SERUM THERAPY IN POLIOMYELITIS
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
测试两种测量湿疹患者睡眠障碍的量表
Journal: British Journal of Dermatology (2020)

特应性皮炎（AD）患者经常会觉得很难入睡，而这些睡眠障碍是由瘙痒、皮肤疼痛和其他 AD 症状引起的。睡眠障碍是临床监测的一个重要领域，而且在试验中，例如测试新的治疗方法或比较不同的治疗方法时，它也是重要的。使用不同的测量方法来评估一个人的睡眠障碍，但是支持这些睡眠障碍测量方法在 AD 患者中的效度的数据有限。
AIDS Exceptionalism
Authors: Mary Bessesen
Journal: Annals of Internal Medicine (1999)

Letters5 January 1999AIDS ExceptionalismRichard Frothingham, MDRichard Frothingham, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-130-1-199901050-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Casarett and Lantos discuss “AIDS exceptionalism” that is based on the argument that “special populations with special needs deserve special considerations” (1). They suggest that special funding for AIDS is unjust, but they neglect two valid arguments for exceptionalism.First, exceptionalism is justified for communicable diseases, such as tuberculosis and measles, that pose a threat to the public health. Special funding allows health departments to provide free tuberculosis medications and childhood immunizations. Infection with HIV poses a greater threat to the U.S. public health than any other epidemic of the 20th century. Special funding is appropriate for ...References1. Casarett DJ, Lantos JD. Have we treated AIDS too well? Rationing and the future of AIDS exceptionalism. Ann Intern Med. 1998;128:756-9. LinkGoogle Scholar2. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-80. CrossrefMedlineGoogle Scholar3. Administration of zidovudine during late pregnancy and delivery to prevent perinatal transmission—Thailand, 1996-1998. MMWR Morb Mortal Wkly Rep. 1998;47:151-4. Google Scholar4. Update: Trends in AIDS incidence—United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:861-7. Google Scholar Author, Article, and Disclosure InformationAuthors: Richard Frothingham, MD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHave We Treated AIDS Too Well? Rationing and the Future of AIDS Exceptionalism David J. Casarett and John D. Lantos AIDS Exceptionalism David Casarett and John Lantos AIDS Exceptionalism Robert K. Bolan AIDS Exceptionalism Mary Bessesen , Marianne McCollum , and BCBS Metrics Cited by“AIDS is Money”: How Donor Preferences Reconfigure Local Realities 5 January 1999Volume 130, Issue 1Page: 80KeywordsAIDSHIVHIV epidemiologyHIV infectionsHIV preventionMeaslesMortalityPopulation statisticsPregnancyPrevention, policy, and public health ePublished: 15 August 2000 Issue Published: 5 January 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Manganese Superoxide Dismutase and Catalase Genetic Polymorphisms, Activity Levels, and Lung Cancer Risk in Chinese in Hong Kong
Authors: James C. Ho, Judith C.W. Mak, S P. Ho, Mary S.M. Ip, Kenneth W. Tsang, W K. Lam, Moira Chan-Yeung
Journal: Journal of Thoracic Oncology (2006)
Mechanism of aplastic anaemia.
Journal: BMJ (1966)

Leading Articles MEDICAL 15 and 16 with hypercortisonism secondary to immunosup- pressive therapy in renal homotransplantation.Finding little evidence of bone necrosis, the authors prefer the title "arthropathy induced by steroid therapy."Although vascular lesions may be responsible for these changes, Velayos and his colleagues found little evidence of this in 'their material.It is clear that destructive changes of bone occur in rheu- matoid arthritis and systemic lupus erythematosus as well as in other disorders.R. D. Gerle12 and his colleagues, for instance, report aseptic necrosis in femoral and humeral heads in association with chronic alcoholic pancreatitis.It is equally clear that similar changes have been reported in asso- ciation with prolonged corticosteroid therapy in a number of unrelated conditions, ranging from eczema to tuberculous pericarditis'3 and thrombocytopenic purpura,'4 where the disease itself would seem unlikely to cause this complication.If Sutton and colleagues9 are right, as they may well be, in regarding it as a rare but important complication of such therapy, careful watch for it in conditions other than rheu- matoid arthritis, such as asthma, should be maintained in the future.
Gynaecological cancer (Abstract No. 394-419)
Authors: Alan Gordon, Dee Hart, Cheryl Bailey, Stephen Anthony, Earl Surwit, Antje Belau, Christian Jackisch, Hans-Joachim Lueck, Barbara Schmalfeldt, Jacobus Pfisterer, Uwe Wagner, Anne Staehle, Willibald Schroeder, Barbara Richter, Andreas Bois
Journal: Annals of Oncology (2002)
Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability
Authors: Beatriz G. Galvez, Maurilio Sampaolesi, Silvia Brunelli, Diego Covarello, Manuela Gavina, Barbara Rossi, Gabriela Costantin, Yvan Torrente, Giulio Cossu
Journal: The Journal of Experimental Medicine (2006)

The IL-1 micrograph in the original version of Fig. 1 B was a duplicate of the C2C12 0 days micrograph in Fig. 1 A. The authors have indicated that this was due to a clerical error during figure preparation.
Fortschritte der Medizin, Munich
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Railroad Rates.
Authors: J. R. Lytle
Journal: JAMA (1897)

Rankin, Ill., April 12, 1897. <h3>To the Editor:</h3> —Will you please inform me what rates can be secured for physicians and their wives for transportation to attend the meeting of theAmerican Medical Associationin June and oblige? Yours truly, <h3>Answer.</h3> —One and one-third fare from all points for the round trip.
Two Germans
Authors: Paula Tatarunis
Journal: Annals of Internal Medicine (1998)

Ad Libitum1 May 1998Two GermansPaula Tatarunis, MDPaula Tatarunis, MDNewton, MA 02167Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-9-199805010-00002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Ignaz Semmelweis,who cut the maternal death ratein the Allgemeines Krankenhausobstetrical wardfrom 18 to 1.2 percentby insisting that the doctorswash their handsbefore and aftereach exam and delivery,so outraged his colleaguesby his findingsthat they hounded himback to Budapestwhere he wroteDie Aetiology der Begriffund die Prophylaxis des Kindbedfiebersand, in 1865, died of sepsisin an insane asylum,a brokenman.In Brockelman's Market,a woman, pregnant,her blouse a colorbetween faded yellowand yellowed white,between spit-up milkand rebleached diapers,a tired woman who, soon,for the sixth time, won'tdie of childbed fever,is buying warmwhiterolls. Author, Article, and Disclosure InformationAffiliations: Newton, MA 02167Corresponding Author: Paula Tatarunis, MD, 10 Crosby Road, Newton, MA 02167. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1998Volume 128, Issue 9Page: 712KeywordsDeath ratesFeversMilkPregnancyProphylaxisSepsis ePublished: 15 August 2000 Issue Published: 1 May 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
KAHN TEST AND WASSERMANN
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AMA grams
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cervical Cancer Screening Every 5 Years OK
Journal: Cancer Discovery (2018)

New cervical cancer screening recommendations from the U.S. Preventive Services Task Force offer many women a new option: being screened every 5 years using high-risk human papillomavirus (HPV) testing. This change reflects new data on HPV testing, but screening every 3 years with a Pap test or every 5 years with both HPV and Pap tests remain options.